• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP:ALPMY)

13.91 +0.01 (+0.07%)
Streaming Delayed Price Updated: 3:58 PM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 80,557
Open 14.24
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 13.90
Today's Range 13.83 - 14.24
52wk Range 8.370 - 14.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
January 26, 2026
The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗
November 12, 2025
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism. 
Via Benzinga

Performance

YTD
+4.4%
+4.4%
1 Month
+4.1%
+4.1%
3 Month
+27.6%
+27.6%
6 Month
+34.5%
+34.5%
1 Year
+42.2%
+42.2%

More News

Read More
News headline image
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients ↗
October 18, 2025
Via Investor's Business Daily
News headline image
Why Is Taysha Gene Therapies Stock Falling Friday? ↗
October 17, 2025
Via Benzinga
News headline image
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients ↗
August 12, 2025
Via Benzinga
News headline image
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study ↗
July 10, 2025
Via Benzinga
News headline image
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗
March 18, 2025
Via Benzinga
News headline image
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo ↗
February 11, 2025
Via Benzinga
News headline image
Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise ↗
January 03, 2025
Via Benzinga
News headline image
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact ↗
December 31, 2024
Via Benzinga
News headline image
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst ↗
October 29, 2024
Via The Motley Fool
News headline image
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗
October 16, 2024
Via Benzinga
News headline image
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗
September 19, 2024
Via Investor's Business Daily
News headline image
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data ↗
August 05, 2024
Via Benzinga
News headline image
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗
February 22, 2024
Via Talk Markets
News headline image
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal ↗
December 31, 2023
Via Talk Markets
News headline image
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗
December 29, 2023
Via Benzinga
News headline image
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks ↗
October 22, 2023
Via Investor's Business Daily
News headline image
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study ↗
October 05, 2023
Via Benzinga
News headline image
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years ↗
September 24, 2023
Via The Motley Fool
News headline image
Why Is Seagen Stock Trading Higher Today? ↗
September 22, 2023
Via Benzinga
News headline image
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer ↗
September 22, 2023
Via Investor's Business Daily
News headline image
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? ↗
September 20, 2023
Via Benzinga
News headline image
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
September 01, 2023
Via MarketBeat
Topics Economy
News headline image
Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin ↗
August 07, 2023
Via Investor's Business Daily

Frequently Asked Questions

Is Astellas Pharma Inc publicly traded?
Yes, Astellas Pharma Inc is publicly traded.
What exchange does Astellas Pharma Inc trade on?
Astellas Pharma Inc trades on the OTC Traded
What is the ticker symbol for Astellas Pharma Inc?
The ticker symbol for Astellas Pharma Inc is ALPMY on the OTC Traded
What is the current price of Astellas Pharma Inc?
The current price of Astellas Pharma Inc is 13.91
When was Astellas Pharma Inc last traded?
The last trade of Astellas Pharma Inc was at 01/29/26 03:58 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap